INLURIYO - (Eq 200MG Base ; Tablet)

Generic Name	IMLUNESTRANT TOSYLATE	**Innovator**	Eli Lilly
Dosage	Eq 200MG Base ; Tablet	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	INLURIYOTM is an estrogen receptor antagonist indicated for: • treatment of adults with ER-positive, HER2-negative, ESR1mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.